Though established for more than a decade, Samba Biologics personnel have a very low profile. That noted, the principal of the firm is identified as having received an NIH grant - not-SBIR - in 2016 addressing a novel post-heart attack therapy anchored in the fact that a heart attack continues to harm cardiac muscle even after the immediate problem a blocked artery is fixed. Samba Biolics personnel are further identified as the researchers having developed a new biologic drug that can preserve blood vessels critical to the bodys blood-pumping system. At the time, the personnel - now Samba Biologic involved - applied for a patent for their developed product - designated VasaPlex - which was also discussed as having potential applications for stroke and peripheral vascular disease.
